280 related articles for article (PubMed ID: 32932517)
21. Comparative studies of somatic and ongoing mutations in immunoglobulin heavy-chain variable region genes in diffuse large B-cell lymphomas of the stomach and the small intestine.
Go JH; Kim DS; Kim TJ; Ko YH; Ra HK; Rhee JC; Kim SW; Ree HJ
Arch Pathol Lab Med; 2003 Nov; 127(11):1443-50. PubMed ID: 14567725
[TBL] [Abstract][Full Text] [Related]
22. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP; Bagirov M; Du Y; Natkunam Y; Khoury HJ; Rossi MR; Harris W; Flowers CR; Lossos IS; Boise LH; Dave SS; Kowalski J; Bernal-Mizrachi L
Oncogene; 2017 Jul; 36(29):4224-4232. PubMed ID: 28368397
[TBL] [Abstract][Full Text] [Related]
23. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
Zheng J; Xu J; Ma S; Sun X; Geng M; Wang L
Int J Clin Exp Pathol; 2013; 6(10):2048-55. PubMed ID: 24133582
[TBL] [Abstract][Full Text] [Related]
25. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
26. Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?
Scott DW; Rimsza LM
Best Pract Res Clin Haematol; 2018 Sep; 31(3):187-198. PubMed ID: 30213388
[TBL] [Abstract][Full Text] [Related]
27. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
28. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
Lenz G; Nagel I; Siebert R; Roschke AV; Sanger W; Wright GW; Dave SS; Tan B; Zhao H; Rosenwald A; Muller-Hermelink HK; Gascoyne RD; Campo E; Jaffe ES; Smeland EB; Fisher RI; Kuehl WM; Chan WC; Staudt LM
J Exp Med; 2007 Mar; 204(3):633-43. PubMed ID: 17353367
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
[TBL] [Abstract][Full Text] [Related]
32. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
34. A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Cen H; Tan X; Guo B
PLoS One; 2015; 10(12):e0145037. PubMed ID: 26716984
[TBL] [Abstract][Full Text] [Related]
35. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
[TBL] [Abstract][Full Text] [Related]
36. Primary Large B-cell Lymphomas of Immune-Privileged Sites.
Roschewski M; Phelan JD; Jaffe ES
Blood; 2024 Apr; ():. PubMed ID: 38635786
[TBL] [Abstract][Full Text] [Related]
37. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
[TBL] [Abstract][Full Text] [Related]
38. [Clinical manifestation and treatment of extranodal diffuse large B-cell lymphoma].
Tomita N
Rinsho Ketsueki; 2016; 57(10):1991-1999. PubMed ID: 27725597
[TBL] [Abstract][Full Text] [Related]
39. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
40. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells.
Ouk C; Roland L; Gachard N; Poulain S; Oblet C; Rizzo D; Saintamand A; Lemasson Q; Carrion C; Thomas M; Balabanian K; Espéli M; Parrens M; Soubeyran I; Boulin M; Faumont N; Feuillard J; Vincent-Fabert C
Front Immunol; 2021; 12():641692. PubMed ID: 34017329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
